- Home
- PLRX vs CRMD Comparison
PLRX vs CRMD Comparison
Compare PLRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CRMD
- Stock Information
- Founded
- PLRX 2015
- CRMD 2006
- Country
- PLRX United States
- CRMD United States
- Employees
- PLRX N/A
- CRMD N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- CRMD Health Care
- Exchange
- PLRX Nasdaq
- CRMD Nasdaq
- Market Cap
- PLRX 680.3M
- CRMD 753.6M
- IPO Year
- PLRX 2020
- CRMD 2010
- Fundamental
- Price
- PLRX $11.37
- CRMD $10.15
- Analyst Decision
- PLRX Strong Buy
- CRMD Strong Buy
- Analyst Count
- PLRX 7
- CRMD 6
- Target Price
- PLRX $40.50
- CRMD $15.67
- AVG Volume (30 Days)
- PLRX 485.5K
- CRMD 1.5M
- Earning Date
- PLRX 02-26-2025
- CRMD 03-11-2025
- Dividend Yield
- PLRX N/A
- CRMD N/A
- EPS Growth
- PLRX N/A
- CRMD N/A
- EPS
- PLRX N/A
- CRMD N/A
- Revenue
- PLRX N/A
- CRMD $12,262,234.00
- Revenue This Year
- PLRX N/A
- CRMD N/A
- Revenue Next Year
- PLRX N/A
- CRMD $246.41
- P/E Ratio
- PLRX N/A
- CRMD N/A
- Revenue Growth
- PLRX N/A
- CRMD 41184.20
- 52 Week Low
- PLRX $10.22
- CRMD $2.89
- 52 Week High
- PLRX $18.00
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- PLRX 44.60
- CRMD 40.80
- Support Level
- PLRX $10.35
- CRMD $11.90
- Resistance Level
- PLRX $11.07
- CRMD $12.67
- Average True Range (ATR)
- PLRX 0.61
- CRMD 0.73
- MACD
- PLRX 0.06
- CRMD -0.27
- Stochastic Oscillator
- PLRX 43.50
- CRMD 2.12
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.